Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* SGA at birth (defined as a length at birth equal or below the tenth percentile according to the Italian reference table of Bertini and Fabris)~* Age of 24 Months~* Caucasic~* Born at term (i.e. after the 37th completed week of gestation)~* Height equal or below (Group A) or up (Group B) the third percentile at the age of 24 months according to the Tanner reference table~* Sufficient GH secretion (more than 10 nanogram (ng)/milliliter (ml)) at least to one of the tests commonly used at that age (glucagon, Levo-dopa, arginine, clonidine, Growth Hormone Releasing Hormone (GHRH), GH integrated secretion)~* Normal level of Thyroid-stimulating hormone (THS), Free Triiodothyronine (FT3), Free Thyroxine (FT4), Insulin-like growth factor 1(IGF-1), insulin and haemoglobin A1c (HbA1c)~* Normal level of Immunoglobulin A (IgA)~* Children parents willing to comply with the protocol for the whole duration of the study~* A written Informed Consent before the baseline visit must be obtained from the parent(s) / legal guardian(s)~Exclusion Criteria:~* Congenital malformations (including Silver-Russel syndrome)~* Known abnormal karyotype, especially in girls~* Twins~* Severe psychomotor retardation~* Previous or ongoing treatment with anabolic steroids or r-hGH~* Treatments interfering with the immune system (including bacterial lysate)~* Severe chronic illnesses~* Autoimmune diseases

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Group A (A1) (Type: EXPERIMENTAL): Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
- Group A (A2) (Type: NO_INTERVENTION): Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
- Group B (Type: NO_INTERVENTION): Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).

Based on this trial design, predict the completion outcome and termination type (if applicable).